Targeting MALT1 in B-cell Lymphomas
Related Experiment Video
Updated: Oct 31, 2026

07:09
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
Huan-Chang Liang1, Kojo S J Elenitoba-Johnson1
1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Blood Cancer Discovery
|October 30, 2026
Abstract:
Safimaltib, a selective allosteric MALT1 protease inhibitor, shows potent antitumor activity in preclinical and clinical studies of B-cell non-Hodgkin lymphomas. See related article by Philippar et al., p. XX See related article by Hertzberg et al., p. XX.

